| Date | Title | | | 07/16/12 | GSK to acquire Human Genome Sciences for US$14.25 per share in cash|
GSK to acquire full ownership of BENLYSTA®,
albiglutide and darapladib
Acquisition will be accretive to GSK core earnings in 2013
Tender offer amended to US$14.25 per share and extended until 27
July 2012
LONDON--(BUSINESS WIRE)--Jul. 16, 2012--
GlaxoSmithKline plc (LSE: GSK) and Human Genome Sciences (NASDAQ: HGSI)
today announced that the companies have entered into a definiti... |
|  | | 07/11/12 | FYI From Human Genome Sciences: GlaxoSmithKline Announces Positive Data from Harmony 8 Phase 3 Trial and Completion of Clinical Registration Package for Albiglutide in Type 2 Diabetes| ROCKVILLE, Md.--(BUSINESS WIRE)--Jul. 11, 2012--
Attached is a press
release issued earlier today by GlaxoSmithKline, announcing
that data have been received from the Phase 3 Harmony 8 study and from
the event-driven meta-analysis for assessment of cardiovascular safety
conducted across the albiglutide clinical program in type 2 diabetes.
These data are the final elements required to complete the clinical
registration package.
A... |
| | | 07/10/12 | Human Genome Sciences Announces Resubmission of Raxibacumab BLA to FDA|
FDA acknowledges receipt and sets PDUFA action date of December 15,
2012
ROCKVILLE, Md.--(BUSINESS WIRE)--Jul. 10, 2012--
Human Genome Sciences, Inc. (Nasdaq: HGSI) announced today that the U.S.
Food and Drug Administration (FDA) has acknowledged receipt of the
resubmission of the Biologics License Application (BLA) for raxibacumab,
a treatment for inhalational anthrax, and has established December 15,
2012 as the P... |
| | | 06/29/12 | Human Genome Sciences Responds To GSK Extension of Unsolicited Tender Offer| ROCKVILLE, Md.--(BUSINESS WIRE)--Jun. 29, 2012--
Human Genome Sciences, Inc. (Nasdaq: HGSI) today issued the following
statement regarding the extension by GlaxoSmithKline plc (GSK) of its
unsolicited tender offer to acquire all the outstanding common shares of
HGS at a price of $13.00 per share in cash and GSK’s statement that
approximately 375,526 shares of HGS common stock have been tendered into
their offer. HGS noted that less than one percent o... |
| | | 06/15/12 | Human Genome Sciences Announces July 16 as the Date for Submission of Definitive Acquisition Proposals| ROCKVILLE, Md.--(BUSINESS WIRE)--Jun. 15, 2012--
Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that, in
connection with its ongoing strategic alternative review process, it had
previously set a bid date of July 16, 2012 for the submission of
definitive proposals to acquire all outstanding common shares of HGS. In
this regard, HGS yesterday sent a letter to GlaxoSmithKline (GSK) once
again inviting GSK to participate in the ongoing proces... |
| | | 06/09/12 | FYI from Human Genome Sciences: GlaxoSmithKline Announces New Data from Phase 3 Studies of Once-Weekly Albiglutide in Type 2 Diabetes|
Detailed 52- and 32-week data from the first two Phase 3 studies of
the investigational once-weekly glucagon-like peptide-1 (GLP-1)
receptor agonist presented at ADA
ROCKVILLE, Md.--(BUSINESS WIRE)--Jun. 9, 2012--
Attached is a press
release issued earlier this morning by GlaxoSmithKline,
announcing that detailed findings from the Harmony 6 Phase 3 study
comparing albiglutide to prandial insulin (Lispro), were pre... |
| | | 06/08/12 | Human Genome Sciences Responds to GSK Extension of Unsolicited Tender Offer| ROCKVILLE, Md.--(BUSINESS WIRE)--Jun. 8, 2012--
Human Genome Sciences, Inc. (Nasdaq: HGSI) today issued the following
statement regarding the extension by GlaxoSmithKline plc (GSK) of its
unsolicited tender offer to acquire all the outstanding common shares of
HGS at a price of $13.00 per share in cash and GSK’s statement that
approximately 474,029 shares of HGS common stock have been tendered into
their offer. HGS noted that less than one percent of... |
| | | 06/05/12 | Human Genome Sciences Announces Multiple Abstracts Related to BENLYSTA® and Systemic Lupus Erythematosus to Be Presented at the 2012 EULAR Annual European Congress of Rheumatology| ROCKVILLE, Md.--(BUSINESS WIRE)--Jun. 5, 2012--
Human Genome Sciences, Inc. (Nasdaq: HGSI) announced today that several
abstracts related to BENLYSTA® (belimumab) and systemic lupus
erythematosus (SLE) will be presented at the EULAR Annual European
Congress of Rheumatology, being held in Berlin, Germany from June 6 to
June 9, 2012. A total of seven abstracts – all posters – have been
accepted for presentation, five clinical trial data abstracts and t... |
| | | 06/04/12 | Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Goldman Sachs Conference| ROCKVILLE, Md.--(BUSINESS WIRE)--Jun. 4, 2012--
Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that its
presentation at the Goldman Sachs 33rd Annual Global Healthcare
Conference will be webcast and may be accessed at www.hgsi.com.
A member of Human Genome Sciences’ senior management team will present a
corporate overview on Tuesday, June 5, 2012, at 5:40 PM Eastern time.
Investors interested in listening to the live webcast may w... |
| | | 06/01/12 | Human Genome Sciences Response to GSK Press Release| ROCKVILLE, Md.--(BUSINESS WIRE)--Jun. 1, 2012--
Human Genome Sciences, Inc. (Nasdaq: HGSI) today issued the following
statement in response to the GlaxoSmithKline plc (GSK) announcement
regarding expiration of the Hart-Scott-Rodino waiting period:
“The HGS Board of Directors has rejected GSK’s unsolicited $13.00 per
share offer, after concluding unanimously that the GSK offer is
inadequate, does not reflect the value inherent in HGS and is no... |
| | | 05/17/12 | Human Genome Sciences Announces Adoption of Short-Term Stockholder Rights Plan| ROCKVILLE, Md.--(BUSINESS WIRE)--May. 17, 2012--
Human Genome Sciences, Inc. (NASDAQ: HGSI) (“HGS” or the “Company”)
announced today that its Board of Directors has adopted a Stockholder
Rights Plan (the “Rights Plan”) and declared a dividend of one share
purchase right (a “Right”) for each share of HGS’s common stock (the
“Common Stock”) held of record at the close of business on May 29, 2012.
The Company’s Board is committed to maximizing s... |
| | | 05/17/12 | Human Genome Sciences Board of Directors Unanimously Determines GlaxoSmithKline Unsolicited Tender Offer is Inadequate and Not in the Best Interests of Stockholders|
Urges stockholders not to tender shares to GSK
HGS filing 14D-9 with SEC providing the basis for the Board’s
decision
ROCKVILLE, Md.--(BUSINESS WIRE)--May. 17, 2012--
Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that its
Board of Directors, after careful review and consideration with the
assistance of the Company’s management and financial and legal advisors,
has unanimously determine... |
| | | 05/09/12 | Human Genome Sciences Board of Directors to Review Unsolicited Tender Offer From GlaxoSmithKline| ROCKVILLE, Md.--(BUSINESS WIRE)--May. 9, 2012--
Human Genome Sciences, Inc. (Nasdaq: HGSI) today confirmed that
GlaxoSmithKline plc (GSK) has announced its intention to commence an
unsolicited tender offer to acquire all the outstanding common shares of
HGS at a price of $13.00 per share in cash.
The HGS Board of Directors, in consultation with independent financial
and legal advisors, will carefully review and consider the offer. The
... |
| | | 04/24/12 | Human Genome Sciences Announces First Quarter 2012 Financial Results| ROCKVILLE, Md., Apr 24, 2012 (BUSINESS WIRE) --Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced financial
results for the quarter ended March 31, 2012, and provided recent
highlights.
"We continue to see quarter-to-quarter progress in BENLYSTA sales," said
H. Thomas Watkins, President and Chief Executive Officer. "A growing
body of evidence from our market research indicates that BENLYSTA is
making a difference for patients with systemic lupus... |
| | | 04/20/12 | Human Genome Sciences to Sponsor Conference Call to Discuss First
Quarter 2012 Financial Results| ROCKVILLE, Md., Apr 20, 2012 (BUSINESS WIRE) --Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that it will
sponsor a conference call to discuss its financial results for the
quarter ended March 31, 2012. These results are expected to be disclosed
on Tuesday, April 24, 2012, after the capital markets close.
The conference call will be hosted by senior management and will be held
on Tuesday, April 24, 2012 at 4:30 pm Eastern Time.
Investors may lis... |
| | | 04/19/12 | Human Genome Sciences Announces Unsolicited Offer from
GlaxoSmithKline; HGS Board of Directors Authorizes Exploration of
Strategic Alternatives|
Board believes $13 unsolicited offer does not reflect value
inherent in Company
Goldman Sachs and Credit Suisse retained to assist with exploration
of strategic alternatives
Additional information requested from GSK
ROCKVILLE, Md., Apr 19, 2012 (BUSINESS WIRE) --Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has
received an unsolicited proposal from GlaxoSmithKline... |
| | | 04/03/12 | FYI from Human Genome Sciences: GlaxoSmithKline Announces Further Data from Phase 3 Trials of Albiglutide| ROCKVILLE, Md.--(BUSINESS WIRE)--Apr. 3, 2012--
Attached is a press
release issued earlier this morning by GlaxoSmithKline,
announcing that topline results have been received from seven of the
eight Harmony Phase 3 studies investigating the use of albiglutide in
type 2 diabetes.
Albiglutide was created by HGS using its proprietary albumin-fusion
technology, and was licensed to GSK in 2004. HGS is entitled to fees and
milestone p... |
| | | 03/20/12 | New Survey Reveals Lupus Communication Gap As Many Patients Remain Silent On True Impact Of Disease| ROCKVILLE, Maryland, and RESEARCH TRIANGLE PARK, NC – March 20, 2012 – Results of a new Roper survey of the lupus community released today highlight a communication gap between people with systemic lupus erythematosus (SLE, lupus) and the people who care for and about them. The Roper survey was designed to evaluate the daily and long-term impact of lupus on health, family relationships, career and quality of life, and identify potential gaps in communication.
The results of the national survey... |
| | | 03/09/12 | Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Barclays Capital Conference| ROCKVILLE, Md.--(BUSINESS WIRE)--Mar. 9, 2012--
Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that its
presentation at the Barclays Capital 2012 Global Healthcare Conference
will be webcast and may be accessed at www.hgsi.com.
A member of Human Genome Sciences’ senior management team will present a
corporate overview on Wednesday, March 14, 2012, at 3:45 PM Eastern
time. Investors interested in listening to the live webcast may w... |
| | | 03/01/12 | Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Cowen and Company Conference| ROCKVILLE, Md.--(BUSINESS WIRE)--Mar. 1, 2012--
Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that its
presentation at the Cowen & Company 32nd Annual Healthcare Conference
will be webcast and may be accessed at www.hgsi.com.
A member of Human Genome Sciences’ senior management team will present a
corporate overview on Monday, March 5, 2012, at 4:50 PM Eastern time.
Investors interested in listening to the live webcast may wa... |
| | | 02/27/12 | Human Genome Sciences Announces Fourth-Quarter and Full-Year Financial Results and Key Developments|
Steady quarter-to-quarter progress for BENLYSTA® sales
HGS ended 2011 with $881 million in cash and investments
ROCKVILLE, Md.--(BUSINESS WIRE)--Feb. 27, 2012--
Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced financial
results for the quarter and full year ended December 31, 2011, and
provided highlights of recent key developments.
“The approval and launch of BENLYSTA for systemic lupus i... |
| | | 02/22/12 | INSERTING and REPLACING Human Genome Sciences to Sponsor Conference Call to Discuss Fourth-Quarter and Full-Year 2011 Financial Results| ROCKVILLE, Md.--(BUSINESS WIRE)--Feb. 22, 2012--
Insert after first paragraph: The conference call will be hosted by
senior management and will be held on Monday, February 27, 2012 at 4:30
pm Eastern time.
The corrected release reads:
HUMAN GENOME SCIENCES TO SPONSOR CONFERENCE CALL TO DISCUSS
FOURTH-QUARTER AND FULL-YEAR 2011 FINANCIAL RESULTS
Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that it will
... |
| | | 02/22/12 | Human Genome Sciences to Sponsor Conference Call to Discuss Fourth-Quarter and Full-Year 2011 Financial Results| ROCKVILLE, Md.--(BUSINESS WIRE)--Feb. 22, 2012--
Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that it will
sponsor a conference call to discuss its financial results for the
fourth-quarter and full-year 2011. These results are expected to be
disclosed on Monday, February 27, 2012, after the capital markets close.
Investors may listen to the call by dialing 888-221-9591 or
913-312-6665, passcode 8441394. A replay of the conferenc... |
| | | 02/13/12 | Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Leerink Swann Conference| ROCKVILLE, Md.--(BUSINESS WIRE)--Feb. 13, 2012--
Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that its
presentation at the Leerink Swann 2012 Global Healthcare Conference will
be webcast and may be accessed at www.hgsi.com.
A member of Human Genome Sciences’ senior management team will present a
corporate overview on Wednesday, February 15, 2012, at 3:00 PM Eastern
time. Investors interested in listening to the live webcast may ... |
| | | 02/10/12 | Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BIO CEO and Investor Conference| ROCKVILLE, Md.--(BUSINESS WIRE)--Feb. 10, 2012--
Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that its
presentation at the 14th Annual BIO CEO & Investor Conference will be
webcast and may be accessed at www.hgsi.com.
A member of Human Genome Sciences’ senior management team will present a
corporate overview on Tuesday, February 14, 2012, at 11:30 AM Eastern
time. Investors interested in listening to the live webcast may wan... |
| | | 01/09/12 | Human Genome Sciences Reports Progress with Commercialization of
BENLYSTA(R) and Announces 2012 Goals at JPMorgan Healthcare Conference|
2011 BENLYSTA(R) gross sales $59.2 million; net sales $52.3 million
Steady progress toward broader adoption of BENLYSTA treatment
ROCKVILLE, Md., Jan 09, 2012 (BUSINESS WIRE) --Human Genome Sciences, Inc. (Nasdaq: HGSI) will today announce its
priority goals for 2012 and report on progress with the
commercialization of BENLYSTA(R) (belimumab), the first approved drug for
systemic lupus... |
| | | 01/09/12 | Human Genome Sciences Reports Progress with Commercialization of BENLYSTA® and Announces 2012 Goals at JPMorgan Healthcare Conference|
2011 BENLYSTA® gross sales $59.2 million; net sales $52.3 million
Steady progress toward broader adoption of BENLYSTA treatment
ROCKVILLE, Md.--(BUSINESS WIRE)--Jan. 9, 2012--
Human Genome Sciences, Inc. (Nasdaq: HGSI) will today announce its
priority goals for 2012 and report on progress with the
commercialization of BENLYSTA® (belimumab), the first approved drug for
systemic lupus in 56 ye... |
| | | 01/05/12 | Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at J.P. Morgan Healthcare Conference| ROCKVILLE, Md.--(BUSINESS WIRE)--Jan. 5, 2012--
Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that its
presentation at the J.P. Morgan 30th Annual Healthcare Conference will
be webcast and may be accessed at www.hgsi.com.
A member of Human Genome Sciences’ senior management team will present a
corporate overview on Monday, January 9, 2012, at 4:30 PM Pacific or
7:30 PM Eastern time. Investors interested in listening to the live
... |
| |
|
